|
Ultrasensitive multiplex detection of structural rearrangements in ALK, RET, ROS1 and PD-L1 using a comprehensive next-generation sequencing assay. |
|
|
Employment - Lucence Diagnostics |
|
|
No Relationships to Disclose |
|
|
Employment - Lucence Diagnostics |
|
|
Employment - Lucence Diagnostics |
|
|
Employment - Lucence Diagnostics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Lucence Diagnostics |
Leadership - Lucence Diagnostics |
Stock and Other Ownership Interests - Lucence Diagnostics |
Patents, Royalties, Other Intellectual Property - Drug delivery technology, diagnostics technology |